Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.01, $0.28 better than the analyst estimate of $0.73. Revenue for the quarter came in at $49.8 million versus the consensus estimate of $47.07 million.

2019 Expense Guidance

• R&D spend in 2019, on a non-GAAP basis, is expected to be $32.0-$36.0 million, as compared to $38.0 million in 2018.
• SG&A spend in 2019, on a non-GAAP basis, is expected to be $51.0-$54.0 million, as compared to $43.0 million in 2018.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.